JPWO2021011808A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021011808A5 JPWO2021011808A5 JP2022502218A JP2022502218A JPWO2021011808A5 JP WO2021011808 A5 JPWO2021011808 A5 JP WO2021011808A5 JP 2022502218 A JP2022502218 A JP 2022502218A JP 2022502218 A JP2022502218 A JP 2022502218A JP WO2021011808 A5 JPWO2021011808 A5 JP WO2021011808A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- sodium
- intragranular
- iii
- total core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875358P | 2019-07-17 | 2019-07-17 | |
| US62/875,358 | 2019-07-17 | ||
| PCT/US2020/042389 WO2021011808A1 (en) | 2019-07-17 | 2020-07-16 | Cardiac sarcomere inhibitor oral formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542804A JP2022542804A (ja) | 2022-10-07 |
| JPWO2021011808A5 true JPWO2021011808A5 (he) | 2023-07-25 |
Family
ID=71995104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502218A Pending JP2022542804A (ja) | 2019-07-17 | 2020-07-16 | 心臓サルコメア阻害剤の経口用製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220265612A1 (he) |
| EP (1) | EP3999038B1 (he) |
| JP (1) | JP2022542804A (he) |
| KR (1) | KR20220082804A (he) |
| CN (1) | CN114765954B (he) |
| AU (1) | AU2020315642A1 (he) |
| BR (1) | BR112022000495A2 (he) |
| CA (1) | CA3144972A1 (he) |
| CL (1) | CL2022000108A1 (he) |
| DK (1) | DK3999038T3 (he) |
| ES (1) | ES2974542T3 (he) |
| FI (1) | FI3999038T3 (he) |
| HR (1) | HRP20240200T1 (he) |
| HU (1) | HUE065712T2 (he) |
| IL (1) | IL289884A (he) |
| LT (1) | LT3999038T (he) |
| MX (1) | MX2022000708A (he) |
| PL (1) | PL3999038T3 (he) |
| PT (1) | PT3999038T (he) |
| RS (1) | RS65302B1 (he) |
| SI (1) | SI3999038T1 (he) |
| TW (1) | TW202116307A (he) |
| WO (1) | WO2021011808A1 (he) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087283A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3843842A1 (en) | 2018-08-31 | 2021-07-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| MX2023010125A (es) | 2021-03-04 | 2023-09-11 | Cytokinetics Inc | Inhibidores del sarcomero cardiaco. |
| WO2023288324A1 (en) | 2021-07-16 | 2023-01-19 | Cytokinetics, Inc. | Methods for treating hypertrophic cardiomyopathy |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| US20240115554A1 (en) | 2022-08-04 | 2024-04-11 | Cytokinetics, Incorporated | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305010A (zh) * | 2005-09-01 | 2008-11-12 | 阿雷生物药品公司 | Raf抑制剂化合物及其用法 |
| UA115979C2 (uk) * | 2009-09-18 | 2018-01-25 | Санофі | Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-3-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю |
| WO2014205234A1 (en) * | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| DK3356345T3 (da) * | 2015-09-30 | 2024-02-12 | Max Planck Gesellschaft | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer |
| CA3087283A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
-
2020
- 2020-07-16 PL PL20753563.4T patent/PL3999038T3/pl unknown
- 2020-07-16 US US17/627,600 patent/US20220265612A1/en active Pending
- 2020-07-16 MX MX2022000708A patent/MX2022000708A/es unknown
- 2020-07-16 TW TW109124113A patent/TW202116307A/zh unknown
- 2020-07-16 WO PCT/US2020/042389 patent/WO2021011808A1/en active Application Filing
- 2020-07-16 CN CN202080062806.7A patent/CN114765954B/zh active Active
- 2020-07-16 AU AU2020315642A patent/AU2020315642A1/en active Pending
- 2020-07-16 HR HRP20240200TT patent/HRP20240200T1/hr unknown
- 2020-07-16 CA CA3144972A patent/CA3144972A1/en active Pending
- 2020-07-16 JP JP2022502218A patent/JP2022542804A/ja active Pending
- 2020-07-16 LT LTEPPCT/US2020/042389T patent/LT3999038T/lt unknown
- 2020-07-16 KR KR1020227003543A patent/KR20220082804A/ko unknown
- 2020-07-16 BR BR112022000495A patent/BR112022000495A2/pt unknown
- 2020-07-16 RS RS20240236A patent/RS65302B1/sr unknown
- 2020-07-16 PT PT207535634T patent/PT3999038T/pt unknown
- 2020-07-16 FI FIEP20753563.4T patent/FI3999038T3/fi active
- 2020-07-16 HU HUE20753563A patent/HUE065712T2/hu unknown
- 2020-07-16 DK DK20753563.4T patent/DK3999038T3/da active
- 2020-07-16 EP EP20753563.4A patent/EP3999038B1/en active Active
- 2020-07-16 ES ES20753563T patent/ES2974542T3/es active Active
- 2020-07-16 SI SI202030397T patent/SI3999038T1/sl unknown
-
2022
- 2022-01-15 CL CL2022000108A patent/CL2022000108A1/es unknown
- 2022-01-16 IL IL289884A patent/IL289884A/he unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3999038T3 (fi) | Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita | |
| US20230011269A1 (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
| US8449910B2 (en) | Stable compositions of famotidine and ibuprofen | |
| JPWO2019152940A5 (he) | ||
| JP2019529570A (ja) | ミドドリンの組成物およびその使用方法 | |
| JP2015515498A (ja) | 新規製剤 | |
| JP2019523258A (ja) | エソメプラゾール、又は薬学的に許容可能なその塩を含むｐＨ依存性薬物放出特性が改善した剤形 | |
| JPWO2021011808A5 (he) | ||
| US20200368185A1 (en) | Combination formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor | |
| US20200222326A1 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
| WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
| JP2018535991A (ja) | ドラビリン、テノホビルジソプロキシルフマル酸塩およびラミブジンを含有する医薬組成物 | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| WO2012002919A1 (en) | Pharmaceutical formulations comprising atorvastatin and aspirin | |
| WO2014006636A2 (en) | Stable compositions of fesoterodine | |
| US20160106763A1 (en) | Oral formulation for the treatment of cardiovascular diseases | |
| WO2011144994A1 (en) | Pharmaceutical compositions of nsaid and acid inhibitor | |
| WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
| WO2020089761A1 (en) | Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof | |
| JP2022140430A5 (he) | ||
| JP2020507621A (ja) | ＨＭＧ−ＣｏＡ還元酵素阻害剤およびクロピドグレルを含む複合製剤 | |
| RU2022103864A (ru) | Пероральные композиции ингибиторов сердечного саркомера | |
| US20210267908A1 (en) | Pharmaceutical compositions of rivaroxaban | |
| WO2017153939A1 (en) | Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof | |
| WO2021094902A1 (en) | Pharmaceutical compositions for major adverse cardiovascular events |